Smoking, vaping linked to higher risk of severe COVID-19 complications, including death

Innovation by MedicalXpress
Jul.27.2022

People who reported smoking or vaping prior to their hospitalization for COVID-19 were more likely than their counterparts who did not smoke or vape to experience severe complications, including death, from the SARS-CoV-2 infection. The findings are from a new study based on data from the American Heart Association's COVID-19 CVD Registry and published in PLOS ONE.

Smoking, vaping linked to higher risk of severe COVID-19 complications, including death

Researchers examined data on people over 18 years of age who were hospitalized with COVID-19 in 107 registry-participating hospitals across the nation between January 2020 to March 2021. Smoking status was self-reported and people were classified as smoking if they reported currently using either traditional, combustible cigarettes or e-cigarette products, with no distinction between the two and no information on duration of smoking or former smoking status. For the final analysis, records were selected for 4,086 people with a 1:2 ratio of people who smoked (1,362) to people who did not smoke (2,724), with the two groups matched for no statistically significant difference in age, sex, race, medical history or medication.

 

The study findings indicate smoking or vaping are associated with more severe COVID-19 independent of age, sex, race or medical history:

  • People who reported smoking were 45% more likely to die and 39% more likely to receive mechanical ventilation when compared with those who did not smoke.
  • Although the excessive risk due to smoking was independent of medical history and medication use, smoking was a stronger risk factor for death in people between 18-59 years of age and those who were white or had obesity.

"In general, people who smoke or vape tend to have a higher prevalence of other health conditions and risk factors that could play a role in how they are impacted by COVID-19. However, the robust and significant increase in the risk of severe COVID-19 seen in our study, independent of medical history and medication use and particularly among young individuals, underscores the urgent need for extensive public health interventions such as anti-smoking campaigns and increased access to cessation therapy, especially in the age of COVID," said the study's senior author, Aruni Bhatnagar, Ph.D., FAHA, a professor of medicine, biochemistry and molecular biology at the University of Louisville in Louisville, Kentucky. "These findings provide the clearest evidence to date that people who smoke or vape have a higher risk of developing severe COVID-19 and dying as a result of SARS-CoV-2 infection."

 

Bhatnagar is co-director of the American Heart Association's Tobacco Center for Regulatory Science which supported the study in part with funding from the U. S. National Institutes of Health and the Food and Drug Administration research grants.

 

"We established the COVID-19 CVD Registry early on in the pandemic to better understand the link between COVID-19 and cardiovascular disease, specifically, to identify increased risk to help inform the diagnosis and care of people who are at highest risk for complications," said Sandeep R. Das, M.D., M.P.H., M.B.A., FAHA, co-chair of the steering committee for the American Heart Association COVID-19 CVD Registry Powered by Get With The Guidelines and director for Quality and Value in the Cardiology Division at UT Southwestern Medical Center in Dallas, Texas. "The findings of this study deliver on that goal and provide invaluable information individuals and their healthcare teams."

 

The American Heart Association launched the registry in 2020 to gather data specific to all patients hospitalized with COVID-19 as part of the Get With The Guidelines quality improvement program. Registry participation was offered at no cost to all U.S. hospitals caring for adults with active COVID-19 and with the infrastructure to support accurate data collection. More than 160 hospitals provided data on more than 79,000 patient records between 2020 and June 2022.

 

The content excerpted or reproduced in this article comes from a third-party, and the copyright belongs to the original media and author. If any infringement is found, please contact us to delete it. Any entity or individual wishing to forward the information, please contact the author and refrain from forwarding directly from here.

British American Tobacco’s Irish unit says VELO pouch sales hit 29m, net revenue climbs to €33.75m
British American Tobacco’s Irish unit says VELO pouch sales hit 29m, net revenue climbs to €33.75m
British American Tobacco’s Irish subsidiary PJ Carroll & Co Ltd reported that sales of its Velo nicotine pouches nearly quintupled in 2024 to 29 million units, driving an 11% year-on-year increase in net revenue to €33.75 million. However, amid a heavy tax burden and declining traditional cigarette volumes, the company’s pre-tax profit fell 8% to €5.69 million.
Dec.01 by 2FIRSTS.ai
SKE Partners with 7-Eleven Korea, Placing Its Products in Over 5,700 Stores
SKE Partners with 7-Eleven Korea, Placing Its Products in Over 5,700 Stores
According to an SKE release published on PR Newswire, the company is expanding its presence in the Korean market through convenience store and specialty retail channels. SKE has partnered with 7-Eleven Korea, placing its products in more than 5,700 stores nationwide, and is also working with OG9’s offline retail and B2B distribution network. On the product side, SKE is focusing on promoting the Crystal Bar TB1000 and Cloud Zero in Korea.
Nov.19 by 2FIRSTS.ai
5th Circuit Reviews FDA’s Compliance on Small-Business Impact of Vape Rule
5th Circuit Reviews FDA’s Compliance on Small-Business Impact of Vape Rule
A Fifth Circuit panel expressed doubts about whether the U.S. Food and Drug Administration complied with the Regulatory Flexibility Act when issuing its 2021 final rule on premarket tobacco product applications. Vape companies argued the FDA relied on outdated and inaccurate economic data, while the government said the challenged requirements stem from the Tobacco Control Act.
Dec.03 by 2FIRSTS.ai
Philip Morris USA Reaches $66M Settlement With Washington State Over MSA Payment Dispute
Philip Morris USA Reaches $66M Settlement With Washington State Over MSA Payment Dispute
Philip Morris USA has reached a settlement with Washington State and agreed to pay $66 million to resolve disputes over annual payments under the 1998 Master Settlement Agreement (MSA) for the period 2005–2015.
Nov.04 by 2FIRSTS.ai
BAT Korea Launches Year-End Promotion for “glo hyper” as Demand for Odorless Heated Tobacco Rises
BAT Korea Launches Year-End Promotion for “glo hyper” as Demand for Odorless Heated Tobacco Rises
BAT Rothmans has announced a year-end promotion for its “glo hyper” heated tobacco series in response to growing consumer demand for odorless devices during the cold season. As indoor activity rises, more smokers are shifting to heated tobacco products that produce less smell and ash. Government data show HNB sales grew 8.3% last year, accounting for 18.4% of the tobacco market.
Nov.12 by 2FIRSTS.ai
2Firsts Observations | Two Months After Launch, BAT’s VELO Shift Draws Attention for Non-Traditional Design as Some Users Call for Higher Nicotine Strength
2Firsts Observations | Two Months After Launch, BAT’s VELO Shift Draws Attention for Non-Traditional Design as Some Users Call for Higher Nicotine Strength
British American Tobacco (BAT) introduced the VELO Shift nicotine pouch in September 2025, featuring a hexagonal outer can and an oval-triangle pouch shape that departs from traditional designs. Two months after launch, the product is available in the U.K., U.S. and Sweden. Social-media feedback indicates the design has been well received, while some users are calling for higher nicotine strength.
Nov.06 by 2FIRSTS.ai